Bringing Shelved Drugs Back to Life

Hundreds of clinical-stage molecules have been shelved for reasons that turned out to be wrong: a failed trial in the wrong patient subtype, a missed mechanism, a side effect that is a feature in another disease. The Drug Rescue Institute systematically mines this graveyard. It re-analyses historical trial data, applies patient subtyping with modern multi-omics, and proposes new indications and trial designs. It also screens repurposing candidates from the broader pharmacopeia — including geroprotector and senolytic candidates — against targets nominated by other institutes. Every rescue thesis is paired with a credibility plan, a virtual trial, and a clear go/no-go threshold. Most rescues will fail. The point is to fail them on paper, not in patients.

Value proposition:

• Re-stratified rescues of shelved clinical assets
• Repurposing tied to causal mechanism, not vibes
• Virtual go/no-go before any new enrollment